Celgene Stock

CELG

Delayed Nasdaq 04:00:00 2019-11-20 pm EST			5-day change	1st Jan Change
108.24 ^USD	+0.10%		-1.97%	+68.89%

23-06-14	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
21-09-07	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI

News in other languages: Celgene

21-04-07	DGAP-WpÜG: Angebot zum Erwerb / Zielgesellschaft: ; Bieter: qqqqq
21-03-25	Leonteq wird neue Emittentin an der BX Swiss AG im Segment «deriBX»
21-02-02	BX Swiss AG startet Handel in neuem Bondsegment
20-07-07	Die BX Swiss AG erhält von der FINMA die Zulassung zur Führung des Schweizer Beraterregisters
20-07-03	Möbel Markt mömax wird neuer Ankermieter im Rüti Center in Pratteln

More news

Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).

Employees

Sector

More about the company

Market Cap	77.04B 66.77B 62.6B 57.08B 107B 7,352B 109B 737B 288B 3,680B 289B 283B 12,277B	P/E 2017	28.7x	P/E 2018	11.6x
Enterprise Value	91.26B 79.1B 74.15B 67.61B 127B 8,710B 129B 873B 341B 4,360B 343B 335B 14,544B	EV / Sales 2017	6.61x	EV / Sales 2018	3.86x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

23-06-14	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
21-09-07	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI
21-06-21	Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity	CI
21-02-22	Celgene Corporation Issues Notice of Redemption of Notes	CI
21-02-04	Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion	CI
21-01-04	Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors	CI
20-12-22	Amgen : Signs Licensing Agreement With Medicines Development for Global Health	MT
20-11-05	Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook	MT
20-09-22	Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors	CI
20-09-21	Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors	CI
20-03-25	Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene	CI
20-03-10	Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors	CI
20-03-04	Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis	CI

23-02-28	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
22-08-24	Not What The Doctor Ordered: Authorisation Application Withdrawn For Pharma Patent Settlement In Australia	AQ
22-07-29	Authorisation request for proposed settlement between pharmaceutical companies withdrawn	AQ
22-02-24	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
21-08-04	Celgene : Sun Pharma And Celegene Settle Patent Dispute Over Lenalidomide (Revlimid®)	AQ

	2017	2018
Net sales	13B 11.27B 10.57B 9.63B 18.13B 1,241B 18.42B 124B 48.57B 621B 48.82B 47.76B 2,072B	15.28B 13.25B 12.42B 11.32B 21.3B 1,458B 21.64B 146B 57.08B 730B 57.37B 56.13B 2,435B
Net income	2.94B 2.55B 2.39B 2.18B 4.1B 281B 4.16B 28.13B 10.98B 140B 11.04B 10.8B 469B	4.05B 3.51B 3.29B 3B 5.64B 386B 5.73B 38.71B 15.11B 193B 15.19B 14.86B 645B
Net Debt	3.79B 3.29B 3.08B 2.81B 5.29B 362B 5.37B 36.29B 14.17B 181B 14.24B 13.93B 604B	14.22B 12.33B 11.56B 10.54B 19.83B 1,357B 20.14B 136B 53.12B 679B 53.39B 52.23B 2,266B

Celgene Stock

Stocks

CELG

Valuation: Celgene

Latest news : Celgene

Press Releases: Celgene

News in other languages: Celgene

Quotes and Performance

Financials

Company Profile